Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY
Large Cap | Pharmaceuticals & Drugs
1175.55
-10.90 (-0.92%)
< Home < Back

Dr. Reddy's Laboratories launches Fesoterodine Fumarate Extended-Release Tablets

Date: 09-07-2022

Dr. Reddy's Laboratories along with its subsidiaries together have launched Fesoterodine Fumarate Extended-Release Tablets, a therapeutic generic equivalent to Toviaz (fesoterodine fumarate) Extended-Release Tablets in the U.S. market following the approval by the U.S. Food and Drug Administration (USFDA).

The Toviaz brand had U.S. sales of approximately $211 million MAT for the most recent twelve months ending in May 2022. Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.